Skip to main content

Search articles in News

Found 2,521 articles

  • BioPartner UK Appoints Strategic Communications Sp

    BioPartner UK Appoints Strategic Communications Specialist Dr Priya Kalia to Advisory Board

    • 7 Feb 2024

    Communications specialist and entrepreneur to help promote expansion of UK-based life sciences trade association focused on growing partnerships

  • 5 Things That Make Ireland a Leading Life Science

    5 Things That Make Ireland a Leading Life Science Hub

    • 7 Feb 2024
    • Lucy Walters

    In this article, we take a closer look at Ireland’s pharmaceutical and life science industry, highlighting the key things that make the country so successful as a leading, global life science hub.

  • New T-FINDER Platform Provides Deep Insights Into

    New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

    • 7 Feb 2024
    • Editor

    Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.

  • IQVIA Named to Fortune® World's Most Admired Compa

    IQVIA Named to Fortune® World's Most Admired Companies™ List, Ranked #1 in Its Sector for the Third Consecutive Year

    • 7 Feb 2024
    • Editor

    IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to the Fortune® World's Most Admired Companies™ list for the seventh consecutive year.

  • 7 Sales and Commercial Career Paths in the Life Sc

    7 Sales and Commercial Career Paths in the Life Science Industry

    • 6 Feb 2024
    • Lucy Walters

    Here, we’ve rounded up 7 Sales and Commercial career paths within the life science industry, outlining the key responsibilities of each role.

  • Dianne Hol appointed new Executive Vice President

    Dianne Hol appointed new Executive Vice President People & Organization at Lundbeck

    • 5 Feb 2024
    • Editor

    H. Lundbeck A/S (Lundbeck) today announced the appointment of Dianne Hol to the role of EVP, People & Organization. Dianne will join Lundbeck on 1 April 2024 and will be part of the Executive Management.

  • Dr Paul Wicks joins precision medicine startup San

    Dr Paul Wicks joins precision medicine startup Sano Genetics as VP of Neuroscience

    • 5 Feb 2024
    • Editor

    Dr Paul Wicks, a neuropsychologist who has worked in the field of ALS (also known as MND) research for 22 years, joins the ranks of precision medicine scaleup Sano Genetics today, where he will take up the full-time role of Vice President of Neuroscience.

  • EMS Healthcare appoints Dr Clare Grace as Chief Ex

    EMS Healthcare appoints Dr Clare Grace as Chief Executive Officer

    • 5 Feb 2024
    • Editor

    EMS Healthcare, a leading provider of flexible medical and clinical research facilities, today announced the appointment of Dr Clare Grace as Chief Executive Officer. Dr Grace joins Cheshire-based EMS Healthcare on the 1st February 2024 from PAREXEL International, where she served as Chief Patient Officer.

  • BenevolentAI Appoints Dr. Joerg Moeller as Chief E

    BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer

    • 5 Feb 2024
    • Editor

    BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the appointment of Dr. Joerg Moeller as Chief Executive Officer and Executive Board member with immediate effect.

  • SPT Labtech Appoints New Chief Commercial Officer

    SPT Labtech Appoints New Chief Commercial Officer

    • 2 Feb 2024
    • Editor

    SPT Labtech is pleased to announce the appointment of Morten Frost Norgreen as Chief Commercial Officer (CCO) as of February 1st, 2024.

  • Cytel Appoints Jovan Willford as Chief Executive O

    Cytel Appoints Jovan Willford as Chief Executive Officer

    • 2 Feb 2024
    • Editor

    Cytel Inc., a leading provider of innovative statistics and health data analytics to the life sciences industry, today announced that Jovan Willford, a dynamic leader known for transformation, growth and a customer-centric approach, has been named Chief Executive Officer and member of its Board of Directors effective immediately.

  • Parexel Appoints Susan R. Salka to Board of Direct

    Parexel Appoints Susan R. Salka to Board of Directors

    • 2 Feb 2024
    • Editor

    Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Susan R. Salka, retired Chief Executive Officer and President of AMN Healthcare Services, Inc., to its Board of Directors. Ms. Salka’s appointment is effective Feb. 1.

  • Maxion Therapeutics Welcomes Dr Arndt Schottelius

    Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO

    • 1 Feb 2024
    • Editor

    Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced today that Dr Arndt Schottelius has been appointed as the new Chief Executive Officer, effective on 1 March 2024, to take the Company to its next phase of development.

  • A Recruiter’s Guide to Hiring a Pharmaceutical Sal

    A Recruiter’s Guide to Hiring a Pharmaceutical Sales Representative

    • 1 Feb 2024
    • Lucy Walters

    To help you identify and engage strong candidates for the role of a pharmaceutical sales representative, we’ve created this short guide to share tips and advice on the candidate qualities to look out for, interview questions to ask, tests and assessments to use during the hiring process, and more.

  • Artificial Intelligence in Medical Writing: An Ins

    Artificial Intelligence in Medical Writing: An Insider’s Insight

    • 31 Jan 2024
    • Editor

    Artificial intelligence (AI) driven large language models (LLMs) such as ChatGPT, are revolutionizing writing tasks through their ability to generate high-quality text. It is crucial therefore to consider the ethical concerns that come with their use and how they are deployed.

  • Robert S. Langer, Co-Founder of Moderna, Joins Lin

    Robert S. Langer, Co-Founder of Moderna, Joins Lindus Health's Advisory Board

    • 31 Jan 2024
    • Editor

    Lindus Health, an anti-CRO running radically faster, more reliable clinical trials for life science pioneers, has announced the appointment of Professor Robert S. Langer, renowned scientist, Institute Professor at Massachusetts Institute of Technology (MIT), and co-founder of Moderna, Inc. to its Advisory Board.

  • Huxley Health Inc. Provides Corporate Update - App

    Huxley Health Inc. Provides Corporate Update - Appoints Bruce Linton as Chairman

    • 31 Jan 2024
    • Editor

    Huxley Health Inc. (“Huxley” or the “Company”) is pleased to provide you with a comprehensive corporate update, highlighting significant milestones and developments that have shaped Huxley over the past year.

  • Boom in life science recruitment leads to ARx expa

    Boom in life science recruitment leads to ARx expansion plans

    • 29 Jan 2024
    • Editor

    ARx, a leading brand in Life Science recruitment services internationally. Coming off the back of a huge year for the company, has entered into their “season of growth” and are creating a whole new team.

  • PharmiWeb Unveils New Branding in Celebration of 2

    PharmiWeb Unveils New Branding in Celebration of 25th Anniversary

    • 29 Jan 2024
    • Lucy Walters

    PharmiWeb, the leading global life science news and jobs portal, is excited to unveil its new branding in line with the company’s 25th anniversary celebrations. This fresh visual identity symbolises PharmiWeb’s commitment to continuous evolution, and to creating a standout user experience for both candidates and clients, whilst still paying homage to the company’s origins.

  • Merck’s KEYTRUDA® (pembrolizumab) Significantly Im

    Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery

    • 29 Jan 2024

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced resectable urothelial carcinoma.